Innovative Industrial Properties, Inc. (IIPR) Earnings Call Transcript
November 4, 2025
Earnings Call Speaker Segments
We appreciate you being on the call. Here with us today are Alan Gold, our Executive Chairman; Paul Smithers, President and Chief Executive Officer; David Smith, Chief Financial Officer; and Ben Regin, Chief Investment Officer. Prior to starting, I want to remind all of you that anything said on this conference call today might be considered forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, and actual results could differ materially because of various risks, uncertainties and other factors. Kindly look at the documents the company has filed with the SEC, in particular the latest reports on Form 10-K and 10-Q, which point out significant risk factors that may lead actual results to differ from those in the forward-looking statements. We have no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events or otherwise. Also, during today's call, we will talk about certain non-GAAP financial information, including FFO, normalized FFO and AFFO. This information, along with reconciliations to the most directly comparable GAAP financial measure, is available in our earnings release issued yesterday and in our 8-K filed with the SEC. I will now turn the call over to Alan. Alan?
Appreciate that, Eli. Morning to everyone, and thanks for being on this call with us. During Q3, we finished making our first investment in IQHQ — a top-tier life sciences real estate platform — which broadened what the company does and should deliver meaningful earnings accretion that benefits IIP shareholders. That investment came to $105 million in total: $100 million went into a revolving credit facility, while $5 million was in preferred stock. The $165 million we still have committed in preferred stock should be funded across several tranches extending to the second quarter of 2027. Alongside that investment, we got a new $100 million secured revolving credit facility closed successfully, which backs our IQHQ investment and makes our balance sheet even stronger. We felt great about how our biggest lender stood behind this facility, and we take it as a sign of ongoing confidence in our platform, our balance sheet, and how carefully we pursue growth and allocate capital. These moves represent a major milestone in our evolution and our shift back toward growth, taking our portfolio past cannabis and into the fast-moving life science space. Our conviction runs deep regarding the long-term fundamentals propelling this industry, and we think making this strategic investment at this particular entry point sets us up to generate strongly accretive returns for our shareholders. We have faith in the worth of our diversified portfolio spanning both cannabis and life science, as well as in our team's capacity to bolster our platform and build long-term value for our shareholders. With that said, I'll hand things over to Paul. Paul?
Appreciate that, Alan, and hello to everybody. Taken together, our IQHQ investment and the new credit facility represent a significant move ahead as we carry out our plan to get back to growth while making our portfolio more varied and stronger. By moving into life sciences, we put ourselves in a position to benefit from long-term secular expansion, and it dovetails with the leadership position we already hold in the regulated cannabis real estate sector; we keep working actively to get the most value out of our assets in order to generate growth and fine-tune performance, and at the same time, the money we've put into IQHQ gives us one more path to growth down the road; in our view, this two-pronged approach will substantially boost shareholder value and set IIP up for lasting success in both industries. Let me give you some concrete updates on where we stand across our portfolio. The receivership process involving 4Front Ventures continues; we're in contact with the U.S. receiver and the bankruptcy trustee about the properties and the associated claims, and we're collaborating closely with outside counsel to safeguard our legal interest and enforce what we're entitled to under the leases. Gold Flora is still in receivership. Talks with the receiver about the receivership and the sale process are continuing; we'll keep watching how things develop and share updates when it makes sense; as for PharmaCann, we're happy to say the judge in Illinois sided with us in our dispute with PharmaCann, and we anticipate getting our Illinois property back by year-end. Our push to also take back control of the properties in New York, Ohio and Pennsylvania stays a top priority. We're continuing to work hand in hand with local counsel to enforce our rights and remedies under the leases and related guarantees, monetary claims included. Since timing differs from state to state and hinges on local jurisdictions, we can't give a specific time line right now. Our focus stays on moving these processes along as efficiently as we can, and we'll share updates whenever developments happen. In September, we regained possession and control of the 4 California properties that had previously secured a loan totaled at $16.1 million, which we declared in default and are weighing options to get the most value out of these assets. Now to federal developments affecting the cannabis industry. Recent remarks from President Trump have reaffirmed that cannabis reform remains a priority at the federal level. His support for medical cannabinoids, especially for senior citizens, along with mentions of the potential $64 billion in health care savings points to growing political momentum for rescheduling cannabis to Schedule III, eliminating the burdensome 280 tax for operators. We think this shift will serve as a positive catalyst for the industry, opening up broader access to capital and speeding up institutional participation, though we remain cautious on the likelihood and timing. We also see compelling demographic trends that reinforce the long-term opportunity in cannabis. Seniors, who currently are underrepresented among cannabis users, are the fastest-growing consumer segment with usage growing at a 9% 5-year compounded annual growth rate, triple the rate of the broader adult population. What matters here is that people in this age group tend to put a lot of weight on what their doctors tell them, so changing how appointments are scheduled might make it simpler for physicians to write prescriptions for cannabis when patients have things like pain, arthritis or sleep disorders. Seniors represent 35% of all money spent on drugs, so we think that if more of them adopt it, that could bring in substantial additional revenue for the sector and give cannabis even stronger credibility as a standard therapeutic choice. We also have some big news on the legal front that we are happy to report. In the prior month, the U.S. Court of Appeals for the Third Circuit ruled unanimously to uphold the District Court's decision to throw out the federal securities class action filed against IIP and some of our officers and directors. From the start, we never agreed with what this class action argued, so having the courts confirm our position feels excellent. With this result, we can keep our attention on carrying out our strategy and creating long-term value for those who hold our shares. At this point I want to hand things over to Ben, who will go through our leasing, disposition and investment activity. Ben?
Appreciate that, Paul. Looking at our cannabis holdings, so far this year we've signed leases amounting to 281,000 square feet at properties in California and Michigan, while also capitalizing on chances to recycle capital through the sale of 2 assets. In addition, we're keeping a close watch on the circumstances involving those tenants Paul mentioned, and the robust demand for our real estate gives us encouragement as we anticipate providing further updates down the road. Shifting to IQHQ, our enthusiasm is high regarding getting back to growth. We finalized our first $105 million investment, with another $165 million in commitments anticipated to be funded gradually. This investment should prove strongly accretive and puts us in position to benefit from long-term tailwinds. Only last month, Lila Sciences, which is an AI biotech firm, signed a lease for 244,000 square feet spanning 2 buildings at IQHQ's Alewife Park property in Cambridge, Massachusetts. That deal stands as one of the biggest leases in the area since the start of the year and highlights both the improving leasing momentum for IQHQ and ongoing appetite for top-tier real estate assets. On the whole, worldwide expenditure on AI along with pharma and biotech is anticipated to hit $3 billion in 2025 and $16.5 billion by 2034, which works out to a 27% CAGR. AI adoption can speed up drug discovery and innovation, leading to a corresponding rise in real estate requirements, as noted by Cushman & Wakefield. We think the IQHQ portfolio, situated in major AI and life science centers in San Diego, San Francisco and Boston, is positioned well to take advantage of these trends; and as part of our investment pipeline, we'll keep selectively chasing assets in the cannabis and life science sectors, concentrating on the finest quality investments offering the most appealing risk-adjusted returns for our shareholders. At this point I'll hand the call over to David.
Thanks, Ben. In Q3, our total revenues came to $64.7 million, which was up 3% versus the previous quarter. The main driver of that gain was a $0.8 million payment tied to the Gold Flora receivership, plus yearly rent increases across our portfolio. Adjusted funds from operations for the quarter came in at $48.3 million, or $1.71 per share, which was unchanged from what we reported in Q2. Our balance sheet is still in great shape, backed by $2.7 billion in gross assets that are mostly unencumbered, along with a capital structure that carries low leverage; we closed the quarter with just under $80 million of liquidity, which includes cash on hand plus what we can draw under our credit facility. As Paul and Alan mentioned earlier, after the quarter ended, we closed a second revolver with a federally regulated bank totaling $100 million, which reflects our belief that as we branch into a new sector, it ought to boost IIP's access to bank financing at attractive pricing. That new revolving credit facility, which is secured by our IQHQ investment, was arranged on favorable terms of SOFR plus 200 basis points, or 6.1% as of the facility's closing date, and it carries an accordion feature allowing capacity to grow to $135 million, contingent on added bank commitments. Together with our low leverage capital structure and solid liquidity, this facility makes certain we have plenty of flexibility to finance future growth. We anticipate our IQHQ investment will be strongly accretive, with a blended interest rate above 14% — that's about 800 basis points more than the pricing currently on the new credit facility — and it fits with our dedication to generating strong risk-adjusted returns for shareholders. As ever, we're committed to keeping a conservative financial profile while chasing strategic opportunities that create long-term value, as shown by our low debt to gross assets ratio of 13% and a debt service coverage ratio above 11x; on the capital markets side, we took advantage of conditions during the quarter to issue 246,000 shares of preferred stock, bringing in total net proceeds of $5.9 million. Going forward, we're actively reviewing our capital structure and are in ongoing talks about our bonds that mature next year, so we can get ahead of that maturity in the near term; we'll keep looking at a variety of strategic financing options consistent with our long-term growth goals and conservative financial approach. With that, we appreciate you joining the call and want to open it up for questions. Operator, would you please open the call for questions?
I'd like to kick things off with the dividend topic, though looking at it from another angle. The way we analyze it, two catalysts in the near term could help close the distance between the $1.71 per share of AFFO you posted in Q3 and the $1.90 quarterly dividend. The first one, which you folks have discussed, is the IQHQ investment — we figure, being fairly cautious, that it can add roughly $0.11 per share on a cash basis once fully deployed. The second is your backfill leases that are signed but haven't commenced yet. Our estimate is that those could bring in somewhere between $0.11 and $0.15 a share each quarter. So on that second bucket, how do you expect the timing of rent commencements to play out at your re-leased assets? And in what way does that timing feed into the company's dividend policy?
Well, I mean — I'm not certain I'm tracking your math precisely. I mean, I think we may be a bit — may hold a somewhat different view regarding the IQHQ investment, but let's take that offline and handle it on its own. On the question of when rent commencements happen on unleased assets, or assets that are — that we're going to get back, bearing in mind that the Gold Flora assets are in a receivership where the receiver, as Paul mentioned, has given the opportunity to an entity that would close on the transaction and then pay rent on the facilities it plans to use, leaving whatever — if any assets remain for us to re-lease, and we believe the timing for receiving income on that would be quite fast given the level of interest we've seen from that portfolio. As for Gold, or as for 4Front, again, going through receivership with the intent of finding a buyer to purchase the entity and then carry on. We think once that wraps up, the revenue would come immediately or very soon after the receivership is done, which could be another, Paul, what's your estimate?
On 4Front, it could be another 3 to 9 months.
Moving on to PharmaCann — and honestly, this speaks well of the sector overall — the attention we're getting on those particular assets, and state by state as well, keeps growing. Getting past the legal hurdles on the Illinois deal makes us happy, and we think there are parties out there who want to take that facility over. The courts had simply kept us from talking with those players. Given how favorably the court responded to what we filed, we expect a lot of interest and the ability to begin generating revenue somewhere between 6 and 9 months from now. Sorry — Paul, why don't you wrap that up.
Sure, a few more things to add there, Tom. Regarding the litigation, my sense is that we're in the fourth quarter of reaching some kind of resolution; securing a trial date across these different jurisdictions takes a very long time. As we've already reported, the outcome in Illinois went our way. My expectation is that Pennsylvania and Ohio come next, whether through a trial or summary judgment, and then at some point after that, New York. So a resolution of those matters is getting close — considerably closer than before. I'd also like to mention that in the bankruptcy cases involving 4Front and Gold Flora, the back rent and the rent that's owed to us counts as an administrative claim within the receivership process. Accordingly, once the receivership wraps up, we ought to receive substantial funds through that administrative claim. And once again, that is — Gold Flora comes sooner than 4Front, but we'll keep reporting on the timing for those.
Great, that's really useful. To build on that a bit, you've signed a few more leases since 2023 wrapped up. Those would be the re-leasing deals with Mitten Extracts, Lume Cannabis, Tri-Mountain Pure, and Berry Green — every one of those backfills that's already been completed. When it comes to the run rate you posted this quarter, that $171 million, how many of those leases have already started contributing to it during this quarter? And how many are still waiting to commence in the near term?
Tom, it's Ben here. Yeah, my sense is it's fairly minimal for Q3. Speaking generally, once we sign a lease, there can be a licensing step, operational ramp-up, and a range of other factors that affect when the revenue actually kicks in. That said, to reinforce what Alan and Paul mentioned, the leasing success has been really pleasing; we're quite optimistic about the demand we're seeing essentially across every asset working through the different legal processes. So pinning down timing is a bit harder, but once again, the demand we're seeing throughout the portfolio has us very encouraged.
All right. Just so I'm clear though, Ben — regarding the ones I brought up, the properties you'd backfilled across the last 2 years — you described their contribution to 3Q as de minimis. That means additional amounts from those are still set to come through. Right?
Correct. I'd say, Tom, on that front, we saw a modest gain, though I'd characterize it as de minimis in this quarter, as those leases come online and ramp up.
And to wrap up in the fourth quarter and beyond.
Excellent. Excellent. All right, so for my last question, I want to talk about the balance sheet. If we think about the sources and uses of funds over the next six months, you obviously mentioned in your prepared remarks that new $100 million revolver, which can continue to support your ongoing investment in IQHQ; as for those unsecured bonds maturing in May, what specific options or types of avenues are you currently looking at? And what's your expectation regarding the timing and getting to a resolution on those?
Well, I'd say the options are about as clear as they could be. Either we refinance them, or we refinance them. That's what we're — those are the choices in front of us right now. We believe we have a very strong and affirmed rating from Egan-Jones and continue to believe our balance sheet is very, very strong, among the strongest in REIT land; and we believe investors are going to recognize how strong our balance sheet is and the fact that we've delivered on our promise to pay on the bonds over the last 4.5 or 4.3 years. And we believe we have enough time to complete the refinancing as they come due next year. And the earliest they can be repaid, I believe, is in the first quarter of 2026.
That's right.
All right, that's great, Alan. So as far as when things happen, we ought to basically figure on wrapping up that process during the first quarter of '26, is that right?
That's the schedule we're working with right now.
So the first question from me is about what rescheduling might actually do. I realize this subject has come up before. I wanted to bring it up once more since, when it comes to the direct effect, it looks like it would mean improved cash and a more solid existing tenant base, which could mean fewer concerns about additional defaults. But what's your thinking on possible growth opportunities, plus more uses for acquisitions and new tenants? Does that depend less on rescheduling and more on additional states launching? I'd just like your wider view on cannabis, considering the supply and demand we've observed across many of the states that already exist, the interest you're seeing for possible extra cultivation, or whether that leans more on new states rather than rescheduling there.
No, I think, as we mentioned earlier in our remarks, we're truly seeing quite encouraging interest in the properties we hold in the states where we do hold properties. So we're seeing ongoing interest from the current growers in those states who have perhaps made it through, or as you'd put it, we believe the consolidation period for this market, for the cannabis industry, appears to have succeeded. It has gotten past most of that consolidation, and the most efficient growers and companies, along with the efficient ones, in that industry have made it through and keep seeking to consolidate, yet expand their emphasis within the individual states where they operate; so we're seeing that favorable early sign there absent rescheduling taking place; and we think that will keep growing over time. And as it grows over time, we are certainly in the strongest position to capitalize on any fresh demand for the sale-leaseback program that we keep providing to the market and to deploy our capital for the good of IIP, our shareholders. Now Paul, I mean, would you like to add anything to — concerning rescheduling and how you believe the effect might be for our tenants?
Right, so Aaron, we've talked before about what rescheduling might look like and the benefits it brings. I believe you pointed out that the earliest genuine effect is an upgrade in operators' credit quality; they simply have far more available cash on hand. That strengthens the credit profile of our tenant base, and it also opens the door for them to put that money toward growth. A large share of our development activity consists of operators growing their current properties and approaching us for further capital; therefore we see that as definitely a potential outcome, or even a probable one, I'd say, should rescheduling occur. And as we mentioned in our prepared comments, enthusiasm around rescheduling tends to swing back and forth. At this point, we've reached a stage where some quite encouraging statements have emerged from the White House, from both the President and his staff, indicating that a resolution on rescheduling is expected before this year ends, which is only, what, 2 months away now; so we're waiting eagerly for it. It's our view that getting in front of this matter politically is a sensible move for the President, and that's how he's motivated. And what he's posted regarding CBD use for — among the elderly and similar topics genuinely creates significant momentum toward reaching some resolution; our expectation is a favorable resolution on rescheduling, ideally before the year is out.
I really value that context—it was useful. Now, looking at the short term: prior to any rescheduling, you mentioned possible chances in both life sciences and cannabis. Given where your liquidity stands right now, how should we weigh near-term priorities? With what we just observed regarding IQHQ and the revolver's rate—presumably tied to IQHQ, and clearly a far superior rate compared to the other revolver linked to cannabis—does life science present more immediate openings? Or, even without rescheduling, do you view both as offering equal potential?
Yes. No, our attention is heavily on cannabis, ensuring we back our tenant partners to the greatest extent possible. That, we feel, is our main priority. On a secondary note, do I believe life science holds additional opportunities yielding double digits or more? We're always evaluating that. Still, I'd say that was a quite distinctive chance we seized thanks to our know-how and insight. We'll keep watching it, but cannabis will, I believe, stay our core emphasis.
The press release brought up, I believe, a handful of fresh names tied to security deposits you're gathering. In Sacramento, one had a name attached while the other did not. Could you tell us how big those are? What result do you anticipate? Also, when you performed that tenant health review earlier in the year, did both of those come up?
Yes, under 1% of our revenue is involved. We keep watch over every tenant, and we invested time with those tenants and grasped what was happening with them. Ben, is there any detail you can share regarding those 2 tenants, or anything else you'd like to include?
Sure, let me add something here. Two tenants in California were part of this, and I think what we're seeing might be a recurring trend in many markets. The efficient operators are growing and expanding, and combined with the demand for these properties, along with some of the other spaces we've reclaimed, it really reflects the consolidation happening across the industry — where operators who aren't as efficient are exiting, while those who are more efficient keep expanding their platforms in these specific markets. I'm quite pleased with how strong those assets are, and I'd say the same about the remainder of our portfolio — something I believe shows up once more in the level of interest we're witnessing pretty much everywhere.
Also, considering the extra square footage that was leased at IQHQ along with the biosciences, where does that bring occupancy at IQHQ? And in the end, where do you anticipate occupancy heading? Perhaps how much time is needed to reach that point? And how much capital do you figure is necessary to push that occupancy rate higher still?
So, I suppose that is — IQHQ is a private entity, so that is truly up to them. As far as we are concerned, the one thing we can state is that the occupancy figure is getting close to that 24%, 25% mark, and we definitely are hopeful they can raise occupancy into the 90-plus percent range over the coming, I guess, 18 to 24 months.
Broadly speaking, if I'm remembering correctly, around the close of last year, roughly 27% of ABR sat in default. It seems you've inked a few fresh — seems you've inked a few replacement deals. You're pursuing certain resolutions and receivership situations, yet a handful of new tenants came in, among them that $16 million loan which turned sour. So on balance, measured against ABR, what's our current position regarding the share of ABR that isn't producing rent? I don't mean space that's occupied — I mean space not generating rent. How much ABR remains non-rent-paying? What's the figure today?
Alex, clearly, ever since we put out that news last December, certain things have shifted as well. We've reclaimed a few properties from PharmaCann, but looking at ABR collection overall, it's approximately 20%.
Alright, so David, where we stand now is — we used to be at 27%, and now we're at 20%, and that 20% takes in the effect of the most recent tenants signed in the third quarter plus that $16 million loan.
Yes, that's right. Just remember, like Alan said earlier, those 2 tenants signed during the quarter were quite small, at 1%, so pretty immaterial to the portfolio as a whole. But you've got it about right.
All right, that sounds good. That sounds good. Moving on — clearly, everyone here respects your life science experience. Alan, you helped start IQHQ and stayed until December, so there's a lot of history there. Yet when you look at both sectors, cannabis still has problems, with tenants facing difficulties. Alexandria, the sole pure-play REIT in that space, life science continues to have troubles. BXP mentions life science troubles too. So we get how solid the balance sheet is today, but it really looks like there could be capital — possible capital requirements for cannabis, and if a senior party at IQHQ does something and you need to protect your position there to protect your stake. So how — I'm still — the danger of entering IQHQ remains unclear, especially since life science isn't past the danger zone. I'd understand if everything were booming and lots of deals were happening in that sector, but it still appears quite distressed; so how do we reconcile the capital requirements of both sectors when even in cannabis, you're still dealing with some tenant problems?
Yeah. I think, above all, we didn't put money in so that we'd end up having to protect that investment. We put money in so that our credit position is extremely strong. And the only — it's the common shareholders at IQHQ and/or the other investors who truly must protect and are truly focused on protecting that business; so that isn't our role or our duty, first of all. Second, we keep a very strong balance sheet, an extremely conservative balance sheet that lets us, as we've just demonstrated, obtain extra credit from our bank group and at a highly appealing yield. So we believe we still have that and keep having excellent access to many capital sources. Third, I realize you all want to — you want companies to invest only when it's completely obvious that the gold ring sits right there and they can simply take it. But our job is to do — is to attempt to see around the bend, to attempt to seek out distinctive investment opportunity that delivers appealing, accretive returns to our shareholders. And that's exactly what we've done; and if you — if 3 years or 4 years from now, you return on the call and you'd like to ask about how IQHQ and that investment turned out, I'll gladly report precisely how that investment turned out.
All right. Then for my last question, Paul, throughout the years, plenty of promising developments have occurred in cannabis — whether it's this ballot initiative, a state granting legal status, or that scheduling change — and each time it seemed almost like a cure-all, as if the sector would finally gain momentum. Of course, I value what you shared in updating us on where things stand with rescheduling and how eager older adults are to take up cannabis. Yet whenever we've gotten encouraging news in the past, it failed to ignite the industry. So do you believe these encouraging developments might ignite the industry? Or is your take that, sure, these are encouraging developments, yet the gray market problem persists, the black market problem persists. All those other issues remain — I suppose I'm simply trying to figure out whether we should feel excited that favorable developments are on the way, or whether it's more like, sure, these are encouraging developments, but plenty of unfavorable factors still confront the industry, specifically the gray market and the black market?
Right, Alex, clearly, a scheduling change won't eliminate the black market. Those are 2 distinct matters requiring distinct solutions. Regarding rescheduling, my belief is it will deliver an enormous boost to the industry for the reasons we've covered at length. Meanwhile, I believe we've witnessed genuine encouraging progress state by state when it comes to fighting the black market. It's far from resolved, but I believe it's drawing considerably more attention in the bigger states. You've observed in California and Massachusetts and Michigan, in particular some truly major — and New York, come to think of it, some truly major progress in reining in black market cultivation, plus gray market retail as well. And I recall you and I talked about this in New York, the actual physical shutdowns of the retail operations; so things are heading in the right direction on that front.
I appreciate it, and I want to thank everyone for being here today. Once more, my thanks go out to our team for the effort and quality they've delivered; and on that note, we bring this call to a close.
Thanks a lot. That brings the call to a close. We appreciate your joining us for the presentation today. You're free to hang up now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Innovative Industrial Properties, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Innovative Industrial Properties, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.